You are here:
NICE
NICE Guidance
Conditions and diseases
Digestive tract conditions
Inflammatory bowel disease
Infliximab and adalimumab for the treatment of Crohn's disease
Technology appraisal guidance
Reference number:
TA187
Published:
19 May 2010
Guidance
Tools and resources
Information for the public
Evidence
History
Research recommendations coming out of this guidance
There are no research recommendations for TA187